- SI-BONE reported third quarter 2026 sales of US$55.7 million and a net loss of US$3.62 million, with full year 2026 revenue guidance reaffirmed at US$231 million to US$233 million.
- The combination of higher year over year sales and a narrower loss, alongside unchanged revenue goals, points to management leaning on operating execution rather than revising its outlook.
- We will now examine how SI-BONE's investment narrative could be shaped by its reaffirmed 2026 revenue guidance after this earnings update.
Compare SI-BONE's reaffirmed outlook with other potential opportunities by scanning our hand-picked list of 21 high quality undiscovered gems that may still be flying under most investors' radars.
SI-BONE Investment Narrative Recap
To own SI-BONE, investors need to believe the firm can turn its focused sacroiliac and spine portfolio into a larger, more efficient procedural platform while steadily narrowing losses. The latest quarter fits that story, with higher sales, a smaller net loss of US$3.62 million and revenue guidance for 2026 kept at US$231 million to US$233 million.
The near term swing factor is execution on procedure volume and pricing as reimbursement changes phase in. The biggest current risk remains quality and recall management, since any extended disruption or added cost could offset operating leverage. On balance, this earnings update does not materially alter that near term setup.
The voluntary Class II recall of selected iFuse TORQ Implant System screws is the announcement that matters most around this print. It goes directly to product reliability in a business where surgeons and hospitals prize consistency, especially for complex pelvic and spine work.
For SI-BONE, effective handling of this recall is tied to both catalysts and risk. Clean field execution helps protect procedure volumes that underpin the reaffirmed revenue outlook, while any missteps could pressure utilization, margins and the rollout of newer devices that are expected to broaden the platform beyond the pelvis.
SI-BONE's narrative projects US$332.1 million revenue and US$42.7 million earnings by 2029, based on analysts assuming 15.9% yearly revenue growth and an earnings increase of about US$57.3 million from earnings today of a US$14.6 million loss.
Uncover why SI-BONE's fair value indicates a 5% potential upside to its current price, which could narrow quickly.
Exploring Other Perspectives
Some bullish analysts frame the upcoming third breakthrough device as the real swing factor for SI-BONE, not the recall. Before this earnings report, the most optimistic forecasts were built on revenue of about US$355.8 million and earnings of roughly US$44.7 million by 2029. Those pre news assumptions might shift, so compare several viewpoints before deciding what makes sense for you.
Explore 4 other SI-BONE fair value estimates, including one that suggests as much as 193% potential upside from the current price!
Reach Your Own Conclusion
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your SI-BONE research is our analysis highlighting 3 key rewards and 2 important warning signs that could impact your investment decision.
- See our latest analysis for SI-BONE. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate SI-BONE's overall financial health at a glance.
Looking for more investment ideas beyond SI-BONE?
Once you have formed a view on SI-BONE, it can help to line that thesis up against a wider watchlist so you can see where risk, income and valuation trade offs look more attractive for your goals.
- For investors who want potential mispricing combined with quality fundamentals, scan a curated set of 42 high quality undervalued stocks that may offer a more attractive entry point than well known large caps.
- If capital preservation is a priority, focus on companies with steadier profiles using a 32 resilient stocks with low risk scores to keep an eye on businesses with more measured risk scores.
- For income focused portfolios, shortlist companies that pay out meaningful cash returns to shareholders through a 6 dividend fortresses with yields above 5%.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com